Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Acalabrutinib maleate by AstraZeneca for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated...
Acalabrutinib maleate by AstraZeneca for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma. According...
Acalabrutinib maleate by AstraZeneca for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma. According...
Acalabrutinib maleate by AstraZeneca for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...
Acalabrutinib maleate by AstraZeneca for Anti-MAG Peripheral Neuropathy: Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Anti-MAG Peripheral Neuropathy. According to GlobalData,...
Acalabrutinib maleate by AstraZeneca for Follicular Lymphoma: Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase III for Follicular Lymphoma. According to GlobalData, Phase...
Acalabrutinib maleate by AstraZeneca for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...
Acalabrutinib maleate by AstraZeneca for Peanut Allergy: Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Peanut Allergy. According to GlobalData, Phase...
Acalabrutinib maleate by AstraZeneca for Graft Versus Host Disease (GVHD): Likelihood of Approval
Acalabrutinib maleate is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD). According...